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Introduction
Recurrent respiratory papillomatosis is commonly asso-
ciated with human papilloma virus type 6 (HPV-6) or
HPV-11. It is seen in both children and adults. The
most commonly involved site is the larynx. Extrala-
ryngeal spread to the lower airway is relatively uncom-
mon.1 The mainstay of treatment is surgery to maintain
a patent airway and improve voice quality. However,
recurrence after surgery is common for most pediatric
patients and for a portion of adults. Because repeated
surgical procedures are required and accompanied by
high morbidity, such as scarring and stenosis,2 adju-
vant therapies, including interferon-α2a, retinoic acid,
indole-3-carbinol, photodynamic therapy, and antiviral
agents, have been applied to decrease the need for
surgery.3 The criteria most practitioners have used for
initiation of adjuvant treatment are: (1) patient under-
goes more than 4 surgical procedures in 1 year; (2) dis-
tal spread of disease; or (3) rapid regrowth with airway
compromise.2 Among the adjuvant agents, cidofovir is
the most frequently used. Cidofovir [(S)-1-(3-hydroxy-
2-phosphonylmethoxypropyl) cytosine; Vistide®, for-
merly known as HPMPC] is an antiviral drug approved
by the US Food and Drug Administration for systemic
use in the treatment of cytomegalovirus retinitis among
HIV/AIDS patients.4 Several studies on cidofovir injec-
tion for treatment of recurrent laryngeal papillomato-
sis (RLP), using different regimens, failed to achieve
therapeutic agreement.5–9 In our clinic, we conducted
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the first cidofovir-injection treatment to assess its effi-
cacy in Taiwanese patients with RLP following excision
of lesions by a microdebrider.
Methods
Beginning from May 2005, 5 patients (2 males; 3
females), 1 of whom was an 8-year-old girl, were
enrolled into our study; they signed informed consent
forms and the use of cidofovir was approved by the
Bureau of Pharmaceutical Affairs, Department of
Health, Taiwan, R.O.C. All patients had a history of
RLP determined by pathology studies. The average
duration of their disease was 71.6 months (range,
9–135 months); they had previously undergone mul-
tiple surgical procedures, either by CO2 laser or other
surgical techniques. The median number of surgical
treatments was 9.4 (range, 4–22).
Videolaryngoscopy was used to record the laryn-
geal lesions. The staging/severity of the disease and
post-cidofovir treatment status were assessed and
scored according to the anatomic staging system de-
veloped by Derkay and colleagues.10 Surgical excision
and intralaryngeal injection procedures were per-
formed with patients under general anesthesia and
direct laryngoscopy.
These procedures were performed by one of the
authors (Y.S. Lin). While the papilloma lesions were
being removed with a microdebrider (2.9-mm Skim-
mer Angle-Tip; XOMED, Jacksonville, FL, USA), cid-
ofovir 7.5 mg/mL was directly injected into the
lesion bed. The injected volume depended on lesion
extension and ranged from 2 mL to 6 mL. Renal and
liver functions were monitored before and during the
treatment period by blood-biochemical parameters to
prevent nephro- and hepatotoxic potentials of cidofovir.
Patients were discharged on the day of surgery
and followed-up every 3 weeks thereafter. At every
follow-up, videolaryngoscopy was performed. Remis-
sions were defined by the absence of gross disease
seen in the office by videolaryngoscopy. Once recur-
rent or new growth lesions were detected in the of-
fice, a repeated intralesional cidofovir injection under
general anesthesia was indicated. No further surgical
excision was performed.
Results
Among the 5 patients, the age at diagnosis of RLP
ranged from 7 to 51 years (Table 1). The pretreat-
ment severity score was 10 ± 3, and the mean follow-up
period was 34.4 weeks (Table 2). The first cidofovir
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Table 1. Patient characteristics
Severity score before cidofovir treatment
Patient Gender Age, yr Age at diagnosis, yr Prior surgeries, n
Total Supraglottis Glottis
1 F 8 7 4 13 4 9
2 F 19 10 22 10 5 5
3 F 44 39 6 5 0 5
4 M 48 44 10 11 5 6
5 M 63 51 5 11 4 7
Table 2. Treatment and follow-up data
Patient
Cidofovir injections, n Severity score after last injection
†
Duration of Duration of
(Total/CR)* Total Supraglottis Glottis CR, wk F/U, wk
‡
1 6/2 4 1 3 14 35
2 5/3 4 0 4 21 39
3 4/2 2 0 2 21 36
4 6/3 6 3 3 11 32
5 5/3 3 1 2 12 30
*Number of total cidofovir injections vs. number of cidofovir injections to complete remission; †score 3 weeks after the first procedure; ‡weeks after the first
procedure. CR = complete remission; F/U = follow-up.
injection was combined with microdebrider excision.
Three weeks after the first injection, all patients pre-
sented with recurrent lesions, and additional cidofovir
injections were then applied at 3-week intervals until
the patients were lesion-free. Following 2–3 repeated
injections, all patients achieved complete remission
ranging from 11 to 21 weeks.
During the follow-up period, patients experienced
different degrees of improvement of their severity
scores; however, none was lesion-free at their last
visit. Patient 4 (male, 48 years old) relapsed 11 weeks
after the first 3 injections, and, subsequently, an addi-
tional 3 injections were conducted over a 9-week
treatment period. Unfortunately, the complication of
partial scar formation over bilateral vocal folds was
noted during his last visit.
Discussion
RLP has been recognized as one of the most challeng-
ing and frustrating disease for both the patients it
afflicts and the physicians who care for them. Although
spontaneous resolution at puberty has been reported in
some children,11 the unpredictability of the illness is
the typical clinical course with RLP affecting both chil-
dren and adults. However, the childhood-onset form is
believed to be more aggressive than the adult form.2
This was the case with Patient 1, who presented the
most severe score before cidofovir treatment.
Until now, the underlying pathophysiology of
HPV infection of the respiratory tract, especially in
the larynx and vocal cords, is not well understood.
The nature of the variability of RLP may explain why
certain individuals require only a few therapeutic pro-
cedures, whereas others require many. Hence, numer-
ous adjuvant medical therapies have been developed.
Cidofovir has demonstrated the most potential for
disease control;12 however, more research is required to
determine efficacy and safety. In this study, we focused
on cidofovir, based on an elucidated pathogenesis of
HPV infection.
Cidofovir is a cytosine nucleotide analog that can
selectively inhibit viral DNA polymerases during viral
replication. In 1998, the first successful use of local
cidofovir injection alone for the treatment of severe
laryngeal papillomatosis was reported.13 Several stud-
ies investigating the efficacy of cidofovir in the man-
agement of recurrent respiratory papillomatosis have
presented encouraging preliminary results,5–8 while
Peyton Shirley and Wiatrak9 and this present study have
not come to a general agreement. Variations among
these surveys consist of inclusion criteria, sample sizes,
affected areas, adjuvant therapy prior to cidofovir, cid-
ofovir dosage, injection interval, and follow-up period.
All of these make the description of cidofovir effect
difficult. Although no general agreement exists on the
curative efficacy of cidofovir, cidofovir injection did
have a significant palliative effect in our patients. All the
patients had decreased severity scores during treatment
and by the end of treatment, which was consistent with
previous reports.
Regarding the concomitant efficacy of cidofovir
and surgical excision, this study showed that 2 or 3 cid-
ofovir injections associated with 1-time microdebrider
excision could attain a varied duration of complete
remission in all of these patients; however, repeated
cidofovir injections even more than 2 times, as in a re-
current follow-up period, was not observed to regress
the lesion completely. This observation would support
the previous work of Naiman and colleagues6 that sur-
gical excision associated with cidofovir injections might
remain necessary in persistent papillomatosis after
cidofovir treatment.
Finally, Patient 4 developed a complication in the
form of scar formation over bilateral vocal folds. In the
literature, vocal-fold scarring that complicated excision
with a microdebrider was never reported. Lee and Rosen
found vocal-fold scarring in 3 patients after recurrent
respiratory papillomatosis was controlled by cidofovir
treatment.8 The present study hardly clarified the issue
of whether the local complication was related to cido-
fovir injection, excision with the microdebrider, or both.
Undoubtedly, the combined treatment can increase the
possibility of scarring.
In conclusion, RLP defied surgical excision and
adjuvant cidofovir injection. The combined treatment
failed to prevent relapse in the case of RLP. Once lesions
recurred, repeated cidofovir injections alone were not
able to achieve complete remission, although these pro-
cedures might have lessened the severity of this dis-
ease. Larger studies and more long-term follow-up are
required to clarify the efficacy of cidofovir.
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